An observational study in Inflammation, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies in Inflammation with a site in China — 38 open to participants now, 39 under way, 1 of them phase 3. Inflammation · China.
Among the 113 studies in Inflammation with a site in China, this one is the 5th largest by planned enrollment of the 39 observational ones that give a count, is one of 7 that started in 2022, is one of 39 observational ones, reaches primary completion later than 30 of the 38 other live ones, and was the 66th registered.
3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.
Browse Inflammation studies →38 of the 113 studies in Inflammation with a site in China are open now. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
Hudson Biotech · Sites in China
Ages 40–75
Hubei Cancer Hospital · Sites in China
Ages 18–70 · Women only
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–65
General Hospital of Shenyang Military Region · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 12 · Phase 3 4 · Phase 4 11
First in 2007; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,400 is above the median of 100 across 864 observational studies indexed under Inflammation.
Median enrollment 100 across the 74 interventional studies, 266 across the 39 observational. Of the 41 that completed or were terminated, 6 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 113 have an industry lead sponsor. The 10 most frequent:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 183 studies on the registry; 146 are open to participants now.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology has 2 studies filed under Inflammation — fewer than ten, so there is no comparison to draw.
12 of the studies in Inflammation with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06968806Phase 3The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolStudy on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection | 2027-09-01 |
| NCT06845410Peking Union Medical College HospitalClinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study | 2026-12 |
| NCT05974904Chongqing Medical UniversityAssociation of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study | 2026-12-28 |
| NCT06966687Nanjing Medical UniversityProtective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI) | 2026-12-31 |
| NCT06730802Nanjing Medical UniversityProtective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII) | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 113 studies in Inflammation with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Coronary artery disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular and cerebrovascular events (MACCE). At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Previous studies indicated that hsCRP ≥ 2mg / L was the definition standard of RIR in CAD in European and American people. In China, the impact of dynamic changes of hsCRP and other inflammatory factors on MACCE in PCI population remains unclear. Therefore, in this study, the investigators plan to recruit patients undergoing PCI, and observe the impact of hsCRP and other inflammatory factors on the prognosis of these patients during long term follow-up at 17 hospitals in China.
The hospitalized patients with coronary heart disease completing all planned PCI
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MACCE
A composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, ischemia-driven revascularization
Time frame: 12 months
all-cause death
Occurrence of all-cause death
Time frame: 12 months
cardiovascular death
Occurrence of cardiovascular death
Time frame: 12 months
nonfatal myocardial infarction
Occurrence of nonfatal myocardial infarction
Time frame: 12 months
nonfatal stroke
Occurrence of of nonfatal stroke
Time frame: 12 months
ischemia-driven revascularization
Occurrence of ischemia-driven revascularization
Time frame: 12 months
hospitalization for unstable angina
Occurrence of hospitalization for unstable angina
Time frame: 12 months
stent/scaffold thrombosis
Occurrence of stent/scaffold thrombosis
Time frame: 12 months
in-stent restenosis
Occurrence of in-stent restenosis
Time frame: 12 months
bleeding
Occurrence of bleeding
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2022 (actual). Primary completion is estimated for Nov 2027, 60 months after the start.
Of 355 non-industry observational studies under Inflammation, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 85. This study's planned 60 months is above that.
Counting every sponsor, half of 371 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology →